10-K/A: Innoviva, Inc. Amends 10-K to Include Audited Financials of Armata Pharmaceuticals

Sentiment:

10-K/A Amendment 24 March 2025 4:15 PM

Innoviva, Inc. files an amendment to its 2024 annual report to include the audited consolidated financial statements of Armata Pharmaceuticals, Inc.

Delay expectedThe filing of the audited consolidated financial statements of Armata Pharmaceuticals, Inc. was delayed, requiring an amendment to the original Form 10-K.

Summary

Innoviva, Inc. has filed an amendment to its Annual Report on Form 10-K for the year ended December 31, 2024.
The amendment includes the audited consolidated financial statements of Armata Pharmaceuticals, Inc. as of December 31, 2024 and 2023, and for the years then ended.
The amendment also includes the consent of Ernst & Young LLP, Armata's independent registered public accounting firm.
The original filing was made on February 26, 2025, and this amendment is being filed to comply with SEC Rule 3-09 of Regulation S-X.
The amendment does not reflect events occurring after the original filing date and does not amend or update the disclosures made in the original filing, except as described in the explanatory note.
The aggregate market value of voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of the registrants Common Stock on The Nasdaq Global Select Market on June 30, 2024 was $899,110,517.
On February 14, 2025, there were 62,675,545 shares of the registrants Common Stock outstanding.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is a regulatory filing, primarily focused on providing financial information. While Armata's financial situation presents challenges, the filing itself is a necessary step for transparency.

Positives

The inclusion of Armata Pharmaceuticals' audited financial statements provides more comprehensive financial information to investors.
The filing is in compliance with SEC regulations, ensuring transparency and regulatory adherence.

Risks

Armata Pharmaceuticals, Inc. has incurred significant operating losses since inception and has primarily relied on equity, debt and grant financing to fund its operations.
As of December 31, 2024, Armata Pharmaceuticals, Inc. had an accumulated deficit of $327.7 million.
The existing cash and cash equivalents of $9.3 million as of December 31, 2024 will not be sufficient to fund its operations for the next 12 months from the date of these consolidated financial statements.
These circumstances raise substantial doubt about Armata Pharmaceuticals, Inc.'s ability to continue as a going concern.
Armata Pharmaceuticals, Inc. may not be able to secure additional financing in a timely manner or on favorable terms, if at all.
If Armata Pharmaceuticals, Inc. is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations.

Future Outlook

Armata Pharmaceuticals plans to raise additional capital through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements.

Industry Context

This filing reflects the ongoing consolidation and strategic investment activity within the biotechnology and pharmaceutical sectors, where companies like Innoviva acquire and manage portfolios of assets like Armata Pharmaceuticals to drive growth and innovation.

Comparison to Industry Standards

It is difficult to compare Innoviva's results to industry standards without specific financial data within the document.
However, the inclusion of Armata's financials allows for a more complete picture of Innoviva's portfolio performance, which can then be compared to peers with similar investment strategies.
Companies like Royalty Pharma and Ligand Pharmaceuticals operate on similar royalty-based models and could be considered peers for comparison once Armata's financial impact is assessed.

Related Party Transactions

Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva Inc., owns 69.3% of Armata Pharmaceuticals, Inc.'s outstanding equity as of December 31, 2024.
Armata Pharmaceuticals, Inc. also received $90.0 million in total debt financing from Innoviva SO during 2023 and in March 2024.
Innoviva designees represent three out of eight seats of Armata Pharmaceuticals, Inc.'s Board of Directors during the year ended December 31, 2024.
On March 12, 2025, Armata Pharmaceuticals, Inc. entered into a credit and security agreement for a loan in an aggregate amount of $10.0 million with Innoviva Strategic Opportunities LLC.

Stakeholder Impact

Shareholders of Innoviva will have access to more complete financial information regarding the company's investments.
Employees of Armata Pharmaceuticals, Inc. face uncertainty due to the company's financial challenges and need for additional funding.
The ability of Armata Pharmaceuticals, Inc. to continue its research and development programs depends on securing additional capital.

Next Steps

Armata Pharmaceuticals, Inc. will need to secure additional financing to continue its operations.
Innoviva will continue to manage its investment in Armata and monitor its financial performance.

Key Dates

Date	Description
January 26, 2021	Effective date of voting agreement between Innoviva Strategic Opportunities LLC and Armata Pharmaceuticals, Inc., expiring on the earlier of the fifth anniversary or FDA approval of a product candidate.
May 23, 2022	Date of Agreement and Plan of Merger among Innoviva, Inc., Innoviva Merger Sub, Inc. and Entasis Therapeutics
July 10, 2022	Date of Agreement and Plan of Merger among Innoviva, Inc., Innoviva Acquisition Sub, Inc. and La Jolla Pharmaceutical Company
January 1, 2023	Date of Amended and Restated Bylaws
January 10, 2023	Date the Company received the Convertible Loan in the aggregate amount of $30.0 million from Innoviva pursuant to the Convertible Credit Agreement.
March 15, 2023	Effective date of Amended and Restated Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities
February 23, 2023	Date of Transition Agreement between Larry Edwards and Innoviva Specialty Therapeutics, Inc.
April 5, 2023	Date of Release of Claims form signed by Larry Edwards
July 28, 2023	Date of Offer Letter between Innoviva, Inc. and Stephen Basso
October 2, 2023	Effective date of Innoviva Clawback Policy
December 31, 2024	Fiscal year end date for Innoviva, Inc. and Armata Pharmaceuticals, Inc.
February 14, 2025	Date on which there were 62,675,545 shares of Innoviva's Common Stock outstanding.
February 26, 2025	Date of the Original Filing of the Annual Report on Form 10-K of Innoviva, Inc.
March 20, 2025	Date of Ernst & Young LLP's report with respect to the consolidated financial statements of Armata Pharmaceuticals, Inc.
March 24, 2025	Date of filing of Amendment No. 1 on Form 10-K/A, including certifications from Innoviva's Principal Executive Officer and Principal Financial Officer.

Keywords

Innoviva, Armata Pharmaceuticals, 10-K/A, Financial Statements, Amendment, Audited Financials

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.